美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

賽生藥業

11.15

0.0000

成交量：- -

成交額：- -

市值：5.82億

市盈率：13.60

高：11.15

開：11.15

低：11.15

收：11.15

52周最高：11.43

52周最低：8.55

股本：5,219.20萬

流通股本：4,527.09萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):0.8200

淨資產收益率：--

總資產收益率：--

市淨率：2.33

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

因購股權獲行使賽生藥業(06600)發行4.5萬股新股份

賽生藥業(06600)於2022年11月回購的40萬股獲註銷

賽生藥業(06600)1月16日根據獲行使購股權計劃發行1.2萬股

從日達仙到多產品蓄勢待發，賽生藥業（6600.HK）成長價值持續兑現

港股異動 | 賽生藥業漲6% 以每股10.06港元提要約回購7753萬股

金融界网站

賽生藥業(06600.HK)每股10.06元提要約回購7,753萬股

阿斯达克财经

賽生藥業(06600.HK)擬溢價約13.93%要約回購並註銷7753.5萬股

金融界网站

賽生藥業(06600)擬溢價約13.93%回購並註銷最多7753.48萬股股份

港股異動 | 賽生藥業(06600)早盤升逾4% 國家藥監局受理Vaborem臨床試驗申請

【港股通】賽生藥業(06600)跌轉漲2.97% 國家藥監局受理Vaborem臨床試驗申請

凤凰网港股

賽生藥業(06600.HK)：藥監局受理抗菌藥物臨床試驗申請

阿斯达克财经

賽生藥業(06600)：國家藥監局受理Vaborem®IND申請

賽生藥業(06600)：Lin Shirley Yi-Hsien獲委任為審核委員會成員

港股異動 | 賽生藥業(06600)跌7% 鼎暉投資數日內減持超11%總股份

賽生藥業(06600)：李泉已辭任非執行董事

智通财经网

港股異動 | 賽生藥業(06600)升逾17% 那西妥單抗獲國家藥監局批准機構看好公司主業盈利能力

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SCLN/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCLN\",,,,,undefined,":{"symbol":"SCLN","market":"US","secType":"STK","nameCN":"賽生藥業","latestPrice":11.15,"timestamp":1515186000000,"preClose":11.15,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":45270936,"shares":52192000,"eps":0.82,"marketStatus":"休市中","change":0,"latestTime":"01-05 16:00:00 EST","open":11.15,"high":11.15,"low":11.15,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.82,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1773043200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":700808400000,"exchange":"NASDAQ","adjPreClose":11.15,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCLN\",,,,,undefined,":{"symbol":"SCLN","floatShares":45270936,"roa":"--","roe":"--","lyrEps":0,"shares":52192000,"dividePrice":0,"high":11.15,"amplitude":0,"preClose":11.15,"low":11.15,"week52Low":8.55,"pbRate":"2.33","week52High":11.425,"institutionHeld":0.4567,"latestPrice":11.15,"eps":0.82,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.82,"open":11.15,"prevYearClose":11.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCLN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-08-09","symbol":"SCLN","fiscalQuarterEnding":"2017/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1502251200000,"reportTimeType":"post","actualEps":0.26},{"market":"US","date":"2017-05-10","symbol":"SCLN","fiscalQuarterEnding":"2017/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1494388800000,"reportTimeType":"post","actualEps":0.29},{"market":"US","date":"2017-03-06","symbol":"SCLN","fiscalQuarterEnding":"2016/12","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1488776400000,"reportTimeType":"pre","actualEps":0.17},{"market":"US","date":"2016-11-09","symbol":"SCLN","fiscalQuarterEnding":"2016/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1478667600000,"reportTimeType":"post","actualEps":0.19},{"market":"US","date":"2016-08-09","symbol":"SCLN","fiscalQuarterEnding":"2016/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1470715200000,"reportTimeType":"","actualEps":0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCLN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SCLN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2308203590","title":"因購股權獲行使 賽生藥業(06600)發行4.5萬股新股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2308203590","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2308203590?lang=zh_tw&edition=fundamental","pubTime":"2023-02-01 20:37","pubTimestamp":1675255078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛生药业(06600)发布公告，于2023年2月1日，该公司因集团员工按行使价2.0462港元行使根据购股权激励计划授出的4.5万份购股权而配发及发行4.5万股新股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/870044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06600","BK1191","SCLN"],"gpt_icon":0},{"id":"2304756987","title":"賽生藥業(06600)於2022年11月回購的40萬股獲註銷","url":"https://stock-news.laohu8.com/highlight/detail?id=2304756987","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2304756987?lang=zh_tw&edition=fundamental","pubTime":"2023-01-20 17:38","pubTimestamp":1674207528,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛生药业(06600)发布公告，于2023年1月20日，公司于2022年11月购回的40万股股份获注销。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/865783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","SCLN","06600"],"gpt_icon":0},{"id":"2303842475","title":"賽生藥業(06600)1月16日根據獲行使購股權計劃發行1.2萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2303842475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2303842475?lang=zh_tw&edition=fundamental","pubTime":"2023-01-16 20:21","pubTimestamp":1673871679,"startTime":"0","endTime":"0","summary":"于本公告日期该等已发行证券的数目如下：合共6.95亿股股份;购股权激励计划项下合共3203.34万份购股权附带权利认购合共3203.34万股股份;及首次公开发售后购股权计划项下合共2151万份购股权附带权利认购合共2151万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/862877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SCLN","06600","BK1191"],"gpt_icon":0},{"id":"2302043127","title":"從日達仙到多產品蓄勢待發，賽生藥業（6600.HK）成長價值持續兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2302043127","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2302043127?lang=zh_tw&edition=fundamental","pubTime":"2023-01-11 08:51","pubTimestamp":1673398316,"startTime":"0","endTime":"0","summary":"荣获“成长价值奖”","market":"hk","thumbnail":"https://img2.gelonghui.com/e78c3-77fe2cc5-7fec-470f-9c5d-f9b5da69698b.png","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/e78c3-77fe2cc5-7fec-470f-9c5d-f9b5da69698b.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/573623","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1191","06600","SCLN"],"gpt_icon":0},{"id":"2302432837","title":"港股異動 | 賽生藥業漲6% 以每股10.06港元提要約 回購7753萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2302432837","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2302432837?lang=zh_tw&edition=fundamental","pubTime":"2023-01-09 09:49","pubTimestamp":1673228972,"startTime":"0","endTime":"0","summary":"格隆汇1月9日丨赛生药业(6600.HK)涨6.12%，报9.37港元，总市值65亿港元。赛生药业8日发布公告，新百利融资将代表该公司提出要约，在该等条件的规限下，按每股股份10.06港元的价格回购并注销最多达最高数目的股份(即7753.48万股股份，占于本公告日期已发行股份约11.16%)。要约将完全根据股份回购守则提出。要约的代价(倘要约获全面接纳，则合共约为7.8亿港元)将以现金支付，并将以集团的内部资源拨付。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2023/01/09094937267283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","06600","SCLN"],"gpt_icon":0},{"id":"2301796812","title":"賽生藥業(06600.HK)每股10.06元提要約  回購7,753萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2301796812","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2301796812?lang=zh_tw&edition=fundamental","pubTime":"2023-01-08 21:00","pubTimestamp":1673182800,"startTime":"0","endTime":"0","summary":"赛生药业(06600.HK) 公布，提出有条件现金要约，回购最多7,753.47万股，占公司股本11.16%；每股作价10.06元，较上交易日(6日)收报溢价13.93%。涉资7.8亿元，将以集团内部资源拨付。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2023-01-06 16:25。)","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190909133502216_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190909133502216_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1237305/latest-news/HK6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1237305/latest-news/HK6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","06600","SCLN"],"gpt_icon":0},{"id":"2301266252","title":"賽生藥業(06600.HK)擬溢價約13.93%要約回購並註銷7753.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2301266252","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2301266252?lang=zh_tw&edition=fundamental","pubTime":"2023-01-06 19:05","pubTimestamp":1673003156,"startTime":"0","endTime":"0","summary":"格隆汇1月6日丨赛生药业公布，新百利融资将代表公司提出要约，在该等条件的规限下，按每股股份10.06港元的价格回购并注销最多达最高数目的股份。要约价较1月6日收市价8.83港元溢价约13.93%。要约将在要约完成及回购股份注销后提高每股盈利并降低集团的资本成本。要约完成及回购股份注销后，全体股东将受益于股东价值提升及资本结构优化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2023/01/06190537265142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SCLN","06600","BK1191"],"gpt_icon":0},{"id":"2301225971","title":"賽生藥業(06600)擬溢價約13.93%回購並註銷最多7753.48萬股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2301225971","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2301225971?lang=zh_tw&edition=fundamental","pubTime":"2023-01-06 18:59","pubTimestamp":1673002794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛生药业 发布公告，新百利融资将代表该公司提出要约，在该等条件的规限下，按每股股份10.06港元的价格回购并注销最多达最高数目的股份。要约完成及回购股份注销后，全体股东将受益于股东价值提升及资本结构优化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/858459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06600","SCLN"],"gpt_icon":0},{"id":"2295663959","title":"港股異動 | 賽生藥業(06600)早盤升逾4% 國家藥監局受理Vaborem臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2295663959","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2295663959?lang=zh_tw&edition=fundamental","pubTime":"2022-12-29 11:55","pubTimestamp":1672286128,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛生药业早盘涨超4%，截至发稿，涨2.73%，报8.64港元，成交额4441.01万港元。消息面上，赛生药业公布，国家药监局药品审评中心正式受理公司新型抗菌药物Vaborem的临床试验申请。此临床研究用于桥接国外临床试验数据，并支持药物最终在中国的上市申请。根据赛生药业2022年8月与美纳里尼集团旗下美纳里尼亚太公司达成的许可及合作协议，赛生药业可根据美纳里尼与Melinta Therapeutics, Inc.此前签订的相关协议，在中国独家开发和商业化Vaborem。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/854135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06600","03347","BK1141","SCLN","BK1576","BK1583"],"gpt_icon":0},{"id":"2295968708","title":"【港股通】賽生藥業(06600)跌轉漲2.97% 國家藥監局受理Vaborem臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2295968708","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2295968708?lang=zh_tw&edition=fundamental","pubTime":"2022-12-29 10:41","pubTimestamp":1672281684,"startTime":"0","endTime":"0","summary":"赛生药业(06600)早盘触底反弹，最新报8.66港元，跌转涨2.97%，成交额2655万港元。公司公布，中国国家药品监督管理局药品审评中心(CDE)正式受理公司新型抗菌药物Vaborem(注射用美罗培南韦博巴坦)的临床试验(IND)申请。此临床试验申请包括一项III期临床研究，其目的是评估Vaborem在中国复杂尿路感染((cUTI)，包括肾盂肾炎)患者中的疗效和安全性；以及一项针对中国健康志愿者的药代动力学研究，以评估Vaborem的药代动力学特征。这两项在中国开展的临床研究用于桥接国外临床试验数据，并支持Vaborem最终在中国的上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=b0d45552060a6ff4b44b73f7c2449c30","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","SCLN","BK1583","BK1191","BK1576","BK1141","06600"],"gpt_icon":0},{"id":"2294753605","title":"賽生藥業(06600.HK)：藥監局受理抗菌藥物臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2294753605","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2294753605?lang=zh_tw&edition=fundamental","pubTime":"2022-12-28 12:18","pubTimestamp":1672201080,"startTime":"0","endTime":"0","summary":"赛生药业(06600.HK) 公布，国家药监局药品审评中心(CDE)正式受理公司新型抗菌药物Vaborem(注射用美罗培南韦博巴坦)的临床试验申请。此临床试验申请包括一项III期临床研究，其目的是评估药物在中国复杂尿路感染(cUTI)，包括肾盂肾炎患者中的疗效和安全性；以及一项针对中国健康志愿者的药代动力学研究，以评估其药代动力学特征。这两项在中国开展的临床研究用于桥接国外临床试验数据，并支持药物最终在中国的上市申请。(sl/k)(港股报价延迟最少十五分钟。沽空资料截至 2022-12-23 16:25。)","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220104144607924_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220104144607924_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1235329/latest-news/HK6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1235329/latest-news/HK6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","03347","06600","BK1141","BK1191","SCLN","BK1576"],"gpt_icon":0},{"id":"2294605501","title":"賽生藥業(06600)：國家藥監局受理Vaborem®IND申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2294605501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2294605501?lang=zh_tw&edition=fundamental","pubTime":"2022-12-28 12:11","pubTimestamp":1672200710,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛生药业 发布公告，中国国家药品监督管理局药品审评中心正式受理公司新型抗菌药物Vaborem的临床试验申请。目前，Vaborem已在美国、欧盟等国家获批用于治疗成人cUTI，包括肾盂肾炎。根据赛生药业2022年8月与美纳里尼集团旗下美纳里尼亚太公司达成的许可及合作协议，赛生药业可根据美纳里尼与Melinta Therapeutics, Inc.此前签订的相关协议，在中国独家开发和商业化Vaborem。公司期待尽快开展此临床试验，以支持Vaborem在中国的上市申请，从而使更多患者获益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/853390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1191","06600","SCLN"],"gpt_icon":0},{"id":"2292828674","title":"賽生藥業(06600)：Lin Shirley Yi-Hsien獲委任為審核委員會成員","url":"https://stock-news.laohu8.com/highlight/detail?id=2292828674","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2292828674?lang=zh_tw&edition=fundamental","pubTime":"2022-12-19 18:11","pubTimestamp":1671444687,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛生药业(06600)发布公告，Lin Shirley Yi-Hsien获委任为审核委员会成员，于2022年12月19日生效。Lin Shirley Yi-Hsien目前为公司非执行董事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/849700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06600","BK1191","SCLN"],"gpt_icon":0},{"id":"2292129846","title":"港股異動 | 賽生藥業(06600)跌7% 鼎暉投資數日內減持超11%總股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2292129846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2292129846?lang=zh_tw&edition=fundamental","pubTime":"2022-12-19 14:23","pubTimestamp":1671431016,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛生药业再度调整，午后跌超7%。其中，鼎晖投资累计抛售超11%公司总股份。截至发稿，赛生药业跌7.66%，报8.20港元，成交额0.76亿港元。联交所最新数据显示，12月8日、12日和15日，赛生药业第二大股东鼎晖投资三度进场减持，累计持仓占比由15.17%降至3.85%。而在12月5日，公司另一机构股东中央汇金减持赛生药业100万股，好仓占比降至11.92%。21年3月上市时，鼎晖投资、中央汇金持股占比分别为15.72%、12.47%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/849289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06600","BK1191","SCLN"],"gpt_icon":0},{"id":"2291609297","title":"賽生藥業(06600)：李泉已辭任非執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2291609297","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2291609297?lang=zh_tw&edition=fundamental","pubTime":"2022-12-13 16:53","pubTimestamp":1670921636,"startTime":"0","endTime":"0","summary":"赛生药业(06600)发布公告，于2022年12月13日，李泉因个人工作安排已辞任...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/846536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["SCLN","BK1191","06600"],"gpt_icon":0},{"id":"2290990271","title":"港股異動 | 賽生藥業(06600)升逾17% 那西妥單抗獲國家藥監局批准 機構看好公司主業盈利能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2290990271","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2290990271?lang=zh_tw&edition=fundamental","pubTime":"2022-12-12 10:21","pubTimestamp":1670811693,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛生药业涨超17%。消息面上，赛生药业日前发公告称，国家药监局近日已批准公司旗下“达佑泽”的生物制品许可申请，其与粒细胞—巨噬细胞集落刺激因子联合给药，可用于治疗伴有骨或骨髓病变，对既往治疗表现为部分缓解、轻微缓解或疾病稳定的1岁及以上儿童或成年复发性或难治性高危神经母细胞瘤患者。赛生药业表示，未来亦将积极寻求扩大使用达佑泽可能解决的疾病适应症。并且主业盈利能力总体稳定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/845533.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SCLN","BK1191","06600"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":86,"code":"91000000","status":"200"}]}}